Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
TP53 and prostate cancer are reported together in 4 articles.
Gene
TP53
- HGNC
- HGNC:11998
219articles
219mentions
7variants with confirmed gene link
Most co-reported phenotypes (articles)
breast cancer 43colorectal cancer 32leukemia 10hepatocellular carcinoma 9ovarian cancer 6thyroid cancer 5lung cancer 4obesity 4
Reported variants (articles · ClinVar status)
Phenotype
Prostate cancer
218articles
218mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
4 records shown · first 60Genomic profiling of urological malignancies using tissue-based next generation sequencing.
PMID 40410007 | DOI 10.1016/j.urolonc.2025.04.011 · Urologic oncology · 2025 · 9 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TP53 | “Prostate cancer commonly involves TMPRSS2-ERG fusions and BRCA2 mutations, affecting treatment strategies, and penile squamous cell carcinoma follows distinct HPV-dependent and HPV-independent pathways, with mutations in TP53 and CDKN2A genes.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “Prostate cancer commonly involves TMPRSS2-ERG fusions and BRCA2 mutations, affecting treatment strategies, and penile squamous cell carcinoma follows distinct HPV-dependent and HPV-independent pathways, with mutations in TP53 and CDKN2A genes.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | VHL | “For instance, renal cell carcinoma frequently harbors alterations in VHL, PBRM1, and BAP1, influencing therapeutic responses, while urothelial carcinoma is characterized by FGFR3 mutations and TERT promoter alterations, which have implications for targeted therapy.” | 0.98 | hgnc_dict_v1 |
| gene | PBRM1 | “For instance, renal cell carcinoma frequently harbors alterations in VHL, PBRM1, and BAP1, influencing therapeutic responses, while urothelial carcinoma is characterized by FGFR3 mutations and TERT promoter alterations, which have implications for targeted therapy.” | 0.98 | hgnc_dict_v1 |
Analyzing the mutational landscape of prostate cancer susceptibility genes through next-generation sequencing (NGS).
PMID 39398597 | PMCID PMC11470312 | DOI 10.62347/QRIF7244 · American journal of translational research · 2024 · 31 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TP53 | “RESULTS: Our study identified genetic mutations in BRCA1, BRCA2, TP53, and PMS2.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “Analyzing the mutational landscape of prostate cancer susceptibility genes through next-generation sequencing (NGS).” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | BRCA1 | “RESULTS: Our study identified genetic mutations in BRCA1, BRCA2, TP53, and PMS2.” | 0.98 | hgnc_dict_v1 |
| gene | BRCA2 | “RESULTS: Our study identified genetic mutations in BRCA1, BRCA2, TP53, and PMS2.” | 0.98 | hgnc_dict_v1 |
PROTACs in the Management of Prostate Cancer.
PMID 37175108 | PMCID PMC10179857 | DOI 10.3390/molecules28093698 · Molecules (Basel, Switzerland) · 2023 · 6 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TP53 | “Genetic alterations and the overexpression of several genes, such as FOXA1, AR, PTEN, RB1, TP53, etc., suppress the immune response, resulting in drug resistance to conventional drugs in prostate cancer.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “PROTACs in the Management of Prostate Cancer.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | FOXA1 | “Genetic alterations and the overexpression of several genes, such as FOXA1, AR, PTEN, RB1, TP53, etc., suppress the immune response, resulting in drug resistance to conventional drugs in prostate cancer.” | 0.98 | hgnc_dict_v1 |
| gene | AR | “Genetic alterations and the overexpression of several genes, such as FOXA1, AR, PTEN, RB1, TP53, etc., suppress the immune response, resulting in drug resistance to conventional drugs in prostate cancer.” | 0.98 | hgnc_dict_v1 |
Identification of Potential Key Genes in Prostate Cancer with Gene Expression, Pivotal Pathways and Regulatory Networks Analysis Using Integrated Bioinformatics Methods.
PMID 35456461 | PMCID PMC9030534 | DOI 10.3390/genes13040655 · Genes · 2022 · 10 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | TP53 | “The key genes, including EGFR, MYC, VEGFA, and PTEN, are targeted by TF such as AR, Sp1, TP53, NF-KB1, STAT3, RELA.” | 0.98 | hgnc_dict_v1 |
| phenotype | prostate cancer | “Identification of Potential Key Genes in Prostate Cancer with Gene Expression, Pivotal Pathways and Regulatory Networks Analysis Using Integrated Bioinformatics Methods.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | EGFR | “The key genes, including EGFR, MYC, VEGFA, and PTEN, are targeted by TF such as AR, Sp1, TP53, NF-KB1, STAT3, RELA.” | 0.98 | hgnc_dict_v1 |
| gene | MYC | “The key genes, including EGFR, MYC, VEGFA, and PTEN, are targeted by TF such as AR, Sp1, TP53, NF-KB1, STAT3, RELA.” | 0.98 | hgnc_dict_v1 |